Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 226

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 226
---
 which Licensed Products are sold
and invoiced, or Revenues are received.

2.6 Place of Payment.
Licensee agrees to pay the respective amounts contemplated by Article 2 to Licensor at the respective addresses listed hereinabove, or
at such other places as Licensor may specify from time to time, in United States dollars and through a United States bank as designated
by Licensor.

2.7 No Duplicate Royalties. No royalty shall be paid twice on a Licensed Product.

2.8 Interest. All payments
due hereunder that are not paid when due and payable as specified in this Agreement shall bear interest at an accrual rate equal to the
prime rate for U.S. dollar deposits in effect from time to time, as published daily in the Wall Street Journal plus 5%, compounded monthly
from the date due until paid, or at such lower rate of interest as shall then be the maximum rate permitted by applicable law.

2.9 Right to Documentation.
Upon request, Licensor shall have the right to request reasonable documentation of Licensee’s calculations to determine Royalties
and to request discussion of such calculations with appropriate representatives of Licensee.

2.10 Records Retention and Audits. Licensee agrees to keep true and accurate records, files, and books of account containing all the data reasonably required
for the full computation and verification of the Royalties to be paid in Article 2 hereof, and Licensee further agrees to permit its books
and records to be examined from time to time to the extent necessary to verify such Royalties, such examination to be made at the expense
of Licensor by any auditor appointed by any of Licensor who shall be acceptable to Licensee, or by a certified public accountant appointed
by Licensor; provided that only those Royalties paid by Licensee within the two (2) year period immediately preceding the start of the
audit, and their supporting records, files, and books of account will be subject to audit.

<div align='center'>ARTICLE 3—GRANT
OF LICENSE AND RIGHT TO SUBLICENSE</div>

3.1 Grant of Exclusive License.
In consideration of and subject to payment of costs and royalties under Article 2 hereof, Licensor hereby grants to Licensee an exclusive
license under the Patent Rights to use, sell and offer to sell Licensed Products in the Licensed Territory and solely in the Field of
Use during the Term of Agreement.

3.2 Grant of Non-exclusive License. In consideration of and subject to payment of